Drugs targeting the binding of NRG1 to ERBB3 and/or the heterodimerization of ERBB2/ERBB3, such as the bispecific monoclonal antibody zenocutuzumab, have demonstrated tumor volume reduction inNRG1fusion-positive tumors. This evidence concerns the gene NRG1 and neoplasm.